Trial Profile
A Phase 3b, Randomized, Open-Label Study to Evaluate Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational
- Sponsors Gilead Sciences
- 31 Oct 2018 Results of a pooled analysis assessing the efficacy and safety of E/C/F/TAF by age in NCT02605954 and NCT02616783 study (n=293) presented at the 14th International Congress on Drug Therapy and HIV Infection
- 31 Oct 2018 Primary endpoint (Percent change from baseline to Week 48 in spine and hip bone mineral density (BMD)) has been met, according to the results presented at the 14th International Congress on Drug Therapy and HIV Infection
- 31 Oct 2018 Results presented at the 14th International Congress on Drug Therapy and HIV Infection